C
Charles D. Blanke
Researcher at University of British Columbia
Publications - 106
Citations - 17049
Charles D. Blanke is an academic researcher from University of British Columbia. The author has contributed to research in topics: Imatinib mesylate & Medicine. The author has an hindex of 33, co-authored 87 publications receiving 16100 citations. Previous affiliations of Charles D. Blanke include University of Michigan & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database
Anna Dorothea Wagner,Axel Grothey,Thierry André,Jesse G. Dixon,Norman Wolmark,Daniel G. Haller,Carmen J. Allegra,Aimery de Gramont,Eric VanCutsem,Steven R. Alberts,Thomas J. George,Michael J. O'Connell,Chris Twelves,Julien Taieb,Leonard B. Saltz,Charles D. Blanke,Edoardo Francini,Rachel Kerr,Greg Yothers,Jean Francois Seitz,Silvia Marsoni,Richard M. Goldberg,Qian Shi +22 more
TL;DR: This study compared incidence and severity of major toxicities of fluoropyrimidine- (5-FU or capecitabine) based adjuvant chemotherapy, with or without oxaliplatin, between male and female patients after curative surgery for colon cancer.
Journal ArticleDOI
Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization.
Abbas Agaimy,Antje Friederike Pelz,Christopher L. Corless,Peter H. Wünsch,Michael Heinrich,Ferdinand Hofstaedter,Wolfgang Dietmaier,Charles D. Blanke,Peter Wieacker,Albert Roessner,Arndt Hartmann,Regine Schneider-Stock +11 more
TL;DR: Carney triad-related GISTs do not only lack conventional KIT and PDGFRA mutations, but they also lack the non-random loss of 14q and 22q characteristic of their sporadic counterparts, suggesting an origin through a distinct pathogenetic pathway.
Journal ArticleDOI
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
Joseph M. Unger,Riha Vaidya,Kathy S. Albain,Michael LeBlanc,Lori M. Minasian,Carolyn C. Gotay,N. Lynn Henry,Michael J. Fisch,Shing M. Lee,Charles D. Blanke,Dawn L. Hershman +10 more
TL;DR: The greater severity of both symptomatic AEs and hematologic AEs in women across multiple treatment modalities indicates that broad-based sex differences exist.
Journal ArticleDOI
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
TL;DR: This regimen of high-dose calcitriol with docetaxel may have activity in incurable pancreatic cancer, with a modest increase in TTP when compared to historical findings using single-agent docetAXel, however, results do not appear superior to those seen with gemcitabine, with or without erlotinib.
Journal ArticleDOI
Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Daniel J. Renouf,Howard John Lim,Caroline Speers,Diego Villa,Sharlene Gill,Charles D. Blanke,Susan E. O'Reilly,Hagen Kennecke +7 more
TL;DR: In this paper, the authors compared survival between referred patients diagnosed with metastatic colorectal cancer (mCRC) in 2003/2004 and 2006 (bevacizumab era).